Switzerland-based Roche Pharma (ROG: SIX) has joined forces with start-up company C4 Therapeutics to develop novel treatments in the field of targeted protein degradation (TPD), it has been announced.
It follows the launch just yesterday (January 7) of USA-based C4 Therapeutics from Dana-Farber Cancer Institute in Massachusetts.
As part of the collaboration, the companies will use C4's Degronimid technology to develop TPD therapeutics for a specific set of target proteins.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze